20240208171546.png)
New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.
New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) continued to make strides against cancer in 2024. Laboratory research teams across the institution worked to advance the global understanding of cancer and to develop new therapies, while also making fundamental insights into human biology and disease.
New research presented during the 2024 San Antonio Breast Cancer Symposium (SABCS) reveals a new machine learning model that could change the way metastatic breast cancer is treated in the future. By combining clinical and genomic data, physician-scientists from Memorial Sloan Kettering Cancer Center (MSK) developed a tool that could help improve predictions of how people with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer respond to CDK4/6 inhibitors, a class of oral medications that control cell division and are often prescribed in combination with hormone therapy to treat this subset of patients.
A new laboratory study provides evidence about how advanced age can be protective against cancer — with implications for treating patients in different age groups.
NEW YORK, December 4, 2024 – Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:
New research from Memorial Sloan Kettering Cancer Center (MSK)& investigates how pancreatic cancer cells regulate their genome to avoid immune attack; shows promise against glioblastoma in mouse models; and develops a new method to study cancer evolution.
New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to “helper” proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Along with defending against pathogens, the body’s innate immune system helps to protect the stability of our genomes in unexpected ways — ways that have important implications for the development of cancer, researchers at MSK are discovering.
Ivan Maillard, MD, PhD, has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
Dr. Deb Schrag, Chair of the Department of Medicine, and Dr. Lorenz Studer, Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.
New research from Memorial Sloan Kettering Cancer Center (MSK) uses saturation genome editing to better understanding of the RAD51C gene, which has been linked to higher risks of breast and ovarian cancer; sheds new light on brain metastasis; and finds a commercially available contrast dye could help surgeons better separate cancer from healthy tissue.
A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.
Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
New research from Memorial Sloan Kettering Cancer Center (MSK) uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare providers about the benefits and risks of commercial genetic testing.
Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments
New research from Memorial Sloan Kettering Cancer Center (MSK) found patients with non-small cell lung cancer brain metastases may benefit from up-front stereotactic radiosurgery; identified a connection between antibiotic use and autoimmune diseases; and uncovered a previously unknown structural role for messenger RNAs in the cytoplasm of cells.
Memorial Sloan Kettering Cancer Center (MSK) announced the following awards and appointments.
New research from Memorial Sloan Kettering Cancer Center (MSK) showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right